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Abstract
Post-translational modification of proteins by small ubiquitin-related modifier (SUMO) is reversible and highly evolutionarily
conserved from yeasts to humans. Unlike ubiquitination with a well-established role in protein degradation, sumoylation
may alter protein function, activity, stability and subcellular localization. Members of SUMO-specific protease (SENP) family,
capable of SUMO removal, are involved in the reversed conjugation process. Although SUMO-specific proteases are known
to reverse sumoylation in many well-defined systems, their importance in mammalian development and pathogenesis
remains largely elusive. In patients with neurodegenerative diseases, aberrant accumulation of SUMO-conjugated proteins
has been widely described. Several aggregation-prone proteins modulated by SUMO have been implicated in
neurodegeneration, but there is no evidence supporting a direct involvement of SUMO modification enzymes in human
diseases. Here we show that mice with neural-specific disruption of SENP2 develop movement difficulties which ultimately
results in paralysis. The disruption induces neurodegeneration where mitochondrial dynamics is dysregulated. SENP2
regulates Drp1 sumoylation and stability critical for mitochondrial morphogenesis in an isoform-specific manner. Although
dispensable for development of neural cell types, this regulatory mechanism is necessary for their survival. Our findings
provide a causal link of SUMO modification enzymes to apoptosis of neural cells, suggesting a new pathogenic mechanism
for neurodegeneration. Exploring the protective effect of SENP2 on neuronal cell death may uncover important preventive
and therapeutic strategies for neurodegenerative diseases.
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Introduction
Emerging evidence suggests the importance of protein modifi-
cation by Small Ubiquitin-related Modifier (SUMO) in neural
development and function [1–3]. Abnormal SUMO modification
has been found in several neurodegenerative diseases, character-
ized by progressive loss or dysfunction of neurons [4–6]. Unlike
ubiquitin with a well-established role in protein degradation,
SUMO is involved in protein trafficking, cell proliferation and
survival, as well as ubiquitin-mediated proteolysis [7–11]. Cova-
lent conjugation of SUMO to protein substrates, also known as
sumoylation, is a reversible process catalyzed by SUMO ligases
[12,13]. The removal of SUMO, also known as desumoylation, is
mediated by SUMO proteases [14,15]. Although these proteins
have been shown to reverse sumoylation in various physiological
systems, their roles in mammalian development and disease
remain largely unknown. SUMO-specific protease 2 (SENP2) is
found in three alternatively spliced forms exhibiting differential
subcellular localizations [16]. Genetic inactivation of Senp2
reveals its requirement in development of trophoblast stem cell
niches and lineages during development of the placenta [17].
Although SENP2 mutants display embryonic defects including
brain and heart abnormalities, they are likely associated with
placental insufficiency which requires further investigation [17,18].
Enhanced sumoylation and accumulation of SUMO-conjugated
proteins have been widely observed in patients with various
neurodegenerative disorders [19–22]. Among the most notable
ones are polyglutamine disorders, including Huntington’s disease
(HD) caused by a trinucleotide expansion, and neuronal intranu-
clear inclusion disease (NIID). The encoded CAG expansions
result in production of toxic proteins carrying extended glutamine
repeats. In HD, SUMO1 conjugation of the disease protein
Huntingtin (Htt) contributes to the disease pathology possibly by
stabilizing the toxic Htt [20]. SUMO-modified targets/substrates
also accumulate in the nuclear aggregates of NIID, a multisystem
neurodegenerative disease characterized by large intranuclear
inclusions in neurons of the central and peripheral nervous systems
[21]. In autosomal recessive juvenile parkinsonism, the SUMO
pathway might affect protein degradation mediated by the disease
protein Parkin, an E3-ubiquitin ligase [23]. Targeting the SUMO
pathway may offer new strategies for disease prevention and
therapy. However, there is no evidence indicating a direct
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involvement of SUMO modification regulators/enzymes in
neurodegenerative disease. Information providing a causal link
of SUMO dysregulation to neural cell survival is also very limited.
Results
SENP2 deficiency causes neurodegeneration
We previously created a mouse strain carrying a null allele of
SENP2 [17]. The knockout of SENP2 led to severe developmental
abnormalities in trophoblast stem cell niches and lineages during
placentation [17]. Although brain and heart deformities were also
detected in the SENP2-null embryos (Figure S1, Maruyama et al.,
unpublished, and [18]), we speculated these are secondary defects
due to placental insufficiencies [17]. To analyze the involvement of
SENP2 and the importance of SUMO modification in neural
development and disease, we first examined its expression pattern.
In situ hybridization detected the presence of SENP2 mRNA in
the developing mouse brain at embryonic day 14.5 (E14.5) and
postnatal day 0 (P0), P7 and P14 (Figure 1A). SENP2 was
expressed in subventricular neural progenitors and differentiated
cells of the cerebral cortex (Figure 1A). To definitively assess our
speculation on the contribution of placental deficiencies to the
embryonic deformities, we took a genetic approach by creating a
mouse model deficient for SENP2 during neural development. A
new mouse strain carrying a SENP2DSUMOFx allele, permitting
removal of the protease core domain using the Cre-loxP system,
was generated (Figure S2). The presence of Cre caused an in-
frame deletion, resulting in production of a SENP2 mutant
deficient for the SUMO protease activity. Using EIIa-Cre to
remove the protease core domain, we generated a mouse strain
carrying SENP2DSUMO mutant allele expressing the truncated
SENP2 (Figure S3). The SENP2DSUMOD/D embryos were
significantly smaller or underdeveloped compared to their
SENP2DSUMO+/+ and SENP2DSUMO+/D littermates at E10.5
(Figure S3A–B). Development of all three trophoblast layers was
severely impaired in the homozygous mutants (Figure S3C–J).
These extraembryonic and embryonic defects are highly reminis-
cent to the SENP2 nulls [17], suggesting that the protease core
domain deletion results in a loss of function mutation. We also
were able to obtain mice heterozygous for the deleted allele
without any noticeable abnormality, further suggesting that there
is no dominant phenotype associated with the mutation.
Next, we generated a SENP2DSUMO-Nes model, in which
SENP2 is ablated in the neural progenitor cells by Nestin-Cre
(Figure S4). At newborn, no obvious defects associated with the
deletion could be detected, including neuronal differentiation (Fu
and Hsu, unpublished), indicating that SENP2 is not essential for
embryonic neural development. The embryonic deformities
observed in the SENP2 nulls were attributed to placental
insufficiency. However, the SENP2DSUMO-Nes mice displayed
movement difficulties at P10. They developed paralysis around
P16 (Figure 1B and Supplementary Video S1; 100% penetrance,
n = 20 SENP2DSUMO-Nes mutants collected from 10 litters), and
died at the age of 3 weeks. The size of the mutant brains was
slightly smaller comparable to the control at P0, but later on
exhibited a gradual reduction (Figure 1B). At P14, the mutant
brain looked transparent, and was much smaller than the control
(Figure 1B; *, p,0.05; **, p,0.01, n = 3). Histology revealed no
obvious defects at P0 but severe brain abnormalities at P7 and P14
associated with the SENP2 deficiency (Figure 1C). The cerebral
cortex of SENP2DSUMO-Nes became significantly thinner and
malformed. Other CNS regions, e.g. midbrain, cerebellum,
hippocampus and spinal cord were also affected by the mutation
although the phenotypes were less severe (Figure S5). The results
suggested an essential role of SENP2 in neural development at
postnatal, but not prenatal, stages.
SENP2 is essential for protection of mitochondria-
dependent apoptosis
The neurodegenerative phenotype of SENP2DSUMO-Nes
prompted us to examine programmed cell death affected by the
mutation. Immunostaining of active Caspase 3 and TUNEL
analysis revealed that abnormal apoptosis is, not detectable at P0,
but increased at P4 (Caspase 3: 0.4660.12% in control vs.
1.5260.33% in mutant) and highly enhanced at P7 (Caspase 3:
0.8260.08% in control vs. 9.460.59% in mutant; TUNEL:
0.9160.17% in control vs. 12.0960.87% in mutant) (Figure 2A,
p,0.01, ,700 cells were counted in each of 3 independent
experiments, mean 6 SEM). The apoptotic abnormality, albeit
less severe at this stage, was also observed in other CNS regions
(Figure S6). To further elucidate the mechanism underlying the
neural cell death of SENP2DSUMO-Nes, we examined expression of
the activated form of Bak, a proapoptotic effector which promotes
programmed cell death through modulation of mitochondrial
morphogenesis [24,25]. In the SENP2DSUMO-Nes cerebral cortices,
Bak activation is stimulated at P0 (1.3960.41% in control vs.
3.0360.17% in mutant) and P7 (3.460.36% in control vs.
8.2160.59% in mutant), suggesting an association of mitochon-
drial dysfunction with the SENP2 mutation (Figure 2B, p,0.01,
,700 cells were counted in each of 3 independent experiments,
mean 6 SEM). Neurons derived from the cerebral cortices of
mouse embryonic brains were then cultured in vitro for
examination of mitochondrial dynamics. Fluorescent labeling of
the mitochondria revealed a more than 2.5-fold increase of
neurons containing fragmented, but not tubular/rod-like, mito-
chondria in the cell body and neurite caused by the mutation
(20.864.4% in control vs. 55.367.8% in mutant) (Figure 2C, p,
0.002, ,200 neurons were counted in each of 3 independent
experiments, mean 6 SEM). Electron microscopy analysis of the
P7 brain sections further identified fragmentation of the
mitochondria in the cerebral cortical neurons of SENP2DSUMO-
Nes (Figure 2D). The mitochondrial cisternae are generally intact
although few of them show alterations on the inner membrane.
The results thus suggested a protective effect of SENP2 on
neuronal cell survival. SENP2 plays an essential role in the
Author Summary
Protein modification by SUMO is a reversible and evolu-
tionarily conserved process. Members of the SUMO-
specific protease (SENP) family are known to reverse
SUMO-conjugation in many defined systems, but their
importance in mammalian development and pathogenesis
remains largely elusive. Although SUMO-conjugated pro-
teins have been shown to aberrantly accumulate in
patients with neurodegeneration, there is no evidence
supporting a direct involvement of SUMO modification
enzymes in human diseases. This study reveals that
disruption of SENP2 causes neurodegeneration through
modulation of mitochondrial morphogenesis. Our findings
provide a causal link of SUMO modification enzymes to cell
survival, suggesting a new pathogenic mechanism for
neurodegeneration. Exploring the protective effect of
SENP2 on neuronal cell death may uncover important
preventive and therapeutic strategies for neurodegenera-
tive diseases.
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regulation of mitochondrial dynamics during postnatal develop-
ment of CNS.
We then examined whether the SENP2 deficiency causes
imbalances of sumoylation, resulting in accumulations of SUMO-
conjugated proteins. Immunostaining of SUMO1 showed in-
creased levels of the sumoylated proteins (26.161.5% in control
vs. 39.464.5% in mutant), indicating that SENP2 deficiency
induces hyper-sumoylation (Figure 3A, p,0.01, ,700 cells were
counted in each of 3 independent experiments, mean 6 SEM).
Although SENP2 was shown to regulate the Mdm2-p53 pathway
[16,17], the expression and the activity of p53 and Mdm2 were
not altered in these mutants (Fu and Hsu, unpublished). The
neural defects caused by the SENP2 deletion most likely were not
associated with p53-induced apoptosis, which is a mitochondrial
independent event. Examination of protein extracts isolated from
the P7 cerebral cortices revealed an elevation of SUMO1
association in the mutants (Figure 3B). The loss of SENP2
activated Bak (Figure 2B), which has been shown to promote
sumoylation of Dynamin regulated protein 1 (Drp1) and its
association with mitochondria during programmed cell death
[24,25]. Therefore, we tested if Drp1 is affected in the
SENP2DSUMO-Nes mutants. Not only the stability (1.9-fold), but
also SUMO1 association with Drp1 (2.7-fold), was enhanced by
the mutation while RanGAP1, a known substrate of SENP2, did
not appear to be affected (Figure 3B). We then examined the
mitochondrial association of Drp1 in primary neurons derived
from the cerebral cortices of mouse embryonic brains. The
mutation apparently promoted Drp1 association with the mito-
chondria (Fig. S7). The results implied that dysregulation of Drp1
may cause mitochondrial defects, leading to the development of
neurodegeneration in the SENP2DSUMO-Nes mutants.
SENP2 in SUMO-mediated regulation of Drp1
Drp1 has been implicated in neural degenerative diseases with
disruption of mitochondrial dynamics [26,27]. To test if Drp1
plays a role in this pathogenic process, we investigated its
regulation by SENP2. Our previous report showed that three
gene products of SENP2 (SENP2, SENP2M and SENP2S),
generated by alternative splicing, leading to the use of distinct
translation initiation sites, exhibit distinct subcellular localizations
Figure 1. Disruption of SENP2 in the neural progenitors causes neurodegeneration. (A) In situ hybridization analysis shows the expression
of SENP2 in the neural progenitors and differentiated cells in the mouse cerebral cortex at embryonic day 14.5 (E14.5), postnatal day 7 (P7). Arrow,
arrowhead and broken line indicate neural progenitors in the subventricular zone, differentiated cells in the cortical plate and outer edge of the
cerebral cortex, respectively. Enlargement of the insets are shown at right. (B) Images show gross morphology of the control and SENP2DSUMO-Nes
brains at P0, P7 and P14, and development of paralysis in the SENP2 mutant (100%, n = 20). Graph illustrates reduction of the brain size caused by the
SENP2 deletion (*, p,0.05; **, p,0.01, n = 3). (C) Hematoxylin and eosin staining analyzes development of the control and SENP2DSUMO-Nes brains at
E14.5, P0, P7 and P14. The genotype for control mice is Nestin-Cre; SENP2SUMOFx/+ or SENP2SUMOFx/Fx. Scale bars, 250 mm (A, left panel); 50 mm (A,
right panel); 3 mm (B); 500 mm (C).
doi:10.1371/journal.pgen.1004579.g001
SENP2 in Neurodegenerative Diseases
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and functions [16]. The SENP2, SENP2M and SENP2S isoforms
are predominately located to the nucleus, cytoplasmic vesicles and
perinuclear region, and cytoplasm, respectively [16]. First, we
examined which of these isoforms might be involved in the
regulation of Drp1 using a parental cell line and its stably
transformed variants, which express high levels of different
isoforms [16]. Whole cells or mitochondria only prepared from
these cell lines were used to isolate extracts, followed by protein
analysis. Overexpression of a HA tagged SUMO1 led to hyper-
sumoylation of total as well as the mitochondrial proteins in the
parental cells which occurs less effectively in all SENP2 variants
(Figure 4A). SUMO1 also promotes total cell, cytoplasmic and
mitochondrial accumulation of Drp1, suggesting that its stability is
modulated by sumoylation. However, this regulatory process, not
affected by SUMO2 and SUMO3, is apparently a SUMO1-
specific regulation (Figure S8A, B). Moreover, high levels of
SENP2S, but not SENP2 and SENP2M, prevented the SUMO1-
induced accumulation of Drp1 to the mitochondria (Figure 4A).
SENP2S also decreased the SUMO1-induced accumulation of
Drp1 in the cytoplasm. Thus suggests that the Drp1 reduction
mediated by SENP2S is caused by protein degradation rather than
decreased targeting to the mitochondria (Figure 4A). Immuno-
precipitation-immunoblot analysis further showed that the SU-
MO1-association of endogenous Drp1 is eliminated by SENP2S,
but not other isoforms (Figure 4B). Although certain levels of
reduction were detected in the SENP2 and SENP2M analyses,
Figure 2. Neuronal cell death caused by the loss of SENP2 is associated with dysregulation of mitochondrial dynamics. (A)
Immunostaining of active (Act.) Caspase3 and TUNEL staining examine apoptotic cells in the P4 and P7 cerebral cortex of control and SENP2DSUMO-Nes.
Graph shows percentages of the positively stained cells (*, p,0.01, n = 3, mean 6 SEM). (B) Immunostaining of the N-terminus and BH-1 domain of the
pro-apoptotic protein Bak, whose exposure indicates its activation, examines the mitochondria-dependent apoptosis in the cerebral cortex of control
(genotype: Nestin-Cre; SENP2SUMOFx/+ and SENP2SUMOFx/Fx) and SENP2DSUMO-Nes at P0 and P7. Graph shows percentages of the Bak positive cells (*, p,
0.01, n = 3, mean 6 SEM). (C) Mitochondrial dynamics of the neurons derived from the P7 cerebral cortex of control and SENP2DSUMO-Nes are analyzed by
MitoTracker labeling. Arrows and arrowheads indicate tubular/rod-like and fragmented mitochondria, respectively. Graph shows percentages of cells
containing fragmented mitochondria (*, p,0.002, n = 3, mean 6 SEM). (D) Sections of the P7 control and SENP2DSUMO-Nes cerebral cortex are examined
by electron microscopy. Arrow indicates alterations of the mitochondria inner membrane. Scale bars, 200 mm (A–B); 20 mm (C); 1 mm (D).
doi:10.1371/journal.pgen.1004579.g002
Figure 3. SENP2 deficiency enhances Drp1 sumoylation and stabilization in the developing cerebral cortex. (A) The overall levels of
sumoylation in the P0 and P7 control (genotype: Nestin-Cre; SENP2SUMOFx/+ and SENP2SUMOFx/Fx) and SENP2DSUMO-Nes brains are assessed by
immunostaining of SUMO1. Graph illustrates percentages of the SUMO1 positive cells at P7 (*, p,0.01, n = 3, mean 6 SEM). (B) Immunoblot (left) and
immunoprecipitation-immunoblot (right) analyses of the P7 control and SENP2DSUMO-Nes brains examines the SUMO modification (brackets), and
protein stability of Drp1 (arrowheads) and RanGAP1 (arrow) affected by the SENP2 mutation. Data shown here are representatives of three
independent experiments. Scale bars, 200 mm (A).
doi:10.1371/journal.pgen.1004579.g003
SENP2 in Neurodegenerative Diseases
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these might be attributed to the disruption of cellular compart-
mentalization in vitro. To further examine the ability of SENP2 to
remove SUMO1 from Drp1, we used in vitro reconstitution
analysis (Figure 4C). Recombinant enzymes, including Ubc9 and
SAE1/2, were first utilized to perform the SUMO1 conjugation of
Drp1. The addition of purified SENP2 efficiently was able to
reverse this sumoylation process (a ,3.8-fold decrease), suggesting
Drp1 as a direct substrate of SENP2 (Figure 4C). Because of
differential subcellular distributions of the SENP2 isoforms
(SENP2 in nucleus; SENP2M in Golgi; SENP2S in cytoplasm)
[16], their co-localizations with Drp1 were then investigated.
Double labeling analysis indicated an extensive co-localization
between Drp1 and SENP2S (Figure 4D). Using a proximity
ligation assay examining protein-protein association within the
cells, we found that SENP2S exhibited an isoform-specific
interaction with Drp1 (Figure 4E). The interaction apparently
took place in the mitochondria and cytoplasm (Figure 4F).
Furthermore, using siRNA specifically knocking down SENP2 to
an expression level at ,17% (Figure 4H), we found that its
reduction promotes Drp1 association with the mitochondria
(Figure 4G), resulting in a 2.2-fold increase compared to the
control (Figure 4H). A mitochondrial protein with higher molec-
ular mass, which is probably the SUMO1-associated Drp1, was
also increased in the SENP2 siRNA treated cells. Consistent with
our analysis in the primary neuron (Figure 2C), the knockdown of
SENP2 also enhanced mitochondrial fragmentation in the cell line
(Figure 4I, p,0.01, ,200 cells were counted in each of 3
independent experiments, mean 6 SEM). These results imply an
isoform-specific effect of SENP2 on Drp1 stabilization and
mitochondrial accumulation through modulation of SUMO1-
specific conjugation.
The isoform-specific regulation of Drp1 by SENP2S suggests its
potential involvement in modulating mitochondrial dynamics.
Using DsRed2-Mito labeling, mitochondrial morphology was
examined in HCT116 and HCT116-SENP2S cells. Similar to
previous findings [28], overexpression of Drp1 and SUMO1
caused fragmentation of the mitochondria in these cells (Fig-
ure 5A–B, A9–B9, I). However, the SUMO1-induced mitochon-
drial fission was prohibited by high levels of SENP2 (Figure 5C,
C9, G, G9, I, p,0.01, ,100 cells were counted in each of 3
independent experiments, mean 6 SEM). This might be
attributed to the regulatory effects of SENP2 on Drp1 sumoylation
and stability. Therefore, we examined if Drp1 is involved in the
SENP2-mediated protection of mitochondrial fragmentation.
High levels of Drp1 were able to overcome the protective effect
of SENP2 on the SUMO1-induced mitochondrial fission (Fig-
ure 5D, D9, H, H9, I, p,0.01, ,300 cells counted, n = 3, mean 6
SEM). In contrast, high levels of SENP2S did not seem to affect
the Drp1-induced mitochondrial fission, suggesting that Drp1 acts
downstream of SENP2S in the regulatory pathway. These results
not only indicated a role of SENP2 in controlling mitochondrial
dynamics but also suggested that SENP2 exerts its effects through
modulation of Drp1.
Discussion
This study demonstrates that SENP2 controls the SUMO1-
mediated modification of Drp1 essential for the regulation of
mitochondrial dynamics. Targeted disruption of SENP2 induces
neurodegeneration through promotion of Drp1 sumoylation and
mitochondrial fragmentation. Impaired desumoylation results in
neural cell death suggesting a new pathogenic mechanism for
neurodegenerative diseases. Dysregulation of several aggregation-
prone proteins which are sumoylation substrates have been
implicated in neurodegeneration [19,20,22,29,30]. However,
there is no evidence showing a direct involvement of SUMO
modification enzymes in human diseases. Our findings suggest that
enhanced sumoylation may also be attributed to mutations in the
SUMO regulators in addition to the substrates. A balanced
sumoylation is pivotal for neuronal cell survival. Hyper-sumoyla-
tion resulting from stimulation of SUMO ligases or disruption of
SUMO proteases can lead to neural cell death. Our findings imply
that targeting the SUMO protease may correct an imbalance of
sumoylation and desumoylation. The SENP2DSUMO-Nes mice
might have potential in modeling human diseases associated with
the SUMO pathway.
An association of the SUMO pathway with the regulation of
mitochondrial dynamics has also been demonstrated in this study.
Mitochondrial dysfunction has a strong association with neurode-
generative diseases [31–33]. Mitochondria possess a highly
dynamic nature, undergoing frequent fusion and fission [34].
Due to large energy demands and long extended processes of the
neurons, they are particularly sensitive and vulnerable to
mitochondrial abnormalities. Enhanced mitochondrial fission
induces apoptosis during neurodegeneration [31–33]. Mitochon-
drial dynamics is regulated by the GTPase dynamin-related
protein Drp1, whose function is modulated by SUMO modifi-
cation. In cells, overexpression of SUMO1 prevents Drp1
degradation, resulting in its stabilization and activation [35].
The SUMO1-induced Drp1 promotes mitochondrial fission
which can be altered by manipulating the SENP activity [36,37].
Data presented in this study strongly suggest that SENP2 is the
physiological enzyme essential for this regulation. SENP2
controls mitochondrial dynamics through modulation of Drp1
Figure 4. SUMO1 modification of Drp1 is regulated by SENP2. (A) Immunoblot (IB) analysis examines total cell expression of HA-SUMO1,
Drp1, myc tagged (MT)-SENP2 isoforms and Actin, as well as the mitochondrial and cytoplasmic expression of Drp1, and Cox IV or Actin, in HCT116
cells and in HCT116 stably transformed variants, HCT116-SENP2, HCT116-SENP2M and HCT116-SENP2S. Overexpression of HA-SUMO1 induces
sumoylation in the total fraction of HCT116 cells and in HCT116 stably transformed variants. The level of Drp1 is only increased in HCT116, HCT116-
SENP2 and HCT116-SENP2M, but not HCT116-SENP2S cells. The level of Actin and Cox IV, a mitochondrial marker, are used as protein loading
controls. (B) Immunoprecipitation (IP) followed by IB analyzes the desumoylation of Drp1 by SENP2 isoforms in HCT116 and HCT116 stably
transformed variants. The SUMO-associated Drp1 is only absent in HCT116-SENP2S, but not HCT116, HCT116-SENP2 and HCT116-SENP2M. (C) In vitro
reconstitution assay using recombinant enzymes and substrates reveals that SUMO conjugation of Drp1 is reversed by purified SENP2. Drp1 is
sumoylated by recombinant Ubc9, SEA1/2 and SUMO1 proteins, followed by desumoylation with purified SENP2. (D) Co-immunostaining of
endogenous Drp1 and transiently expressed myc tagged SENP2 isoforms examines their subcellular localizations. Images are enlargements of the
insets shown at right. (E) Association of endogenous Drp1 and different SENP2 isoforms is determined by proximity ligation assay using a Duolink
system detecting in-cell protein interaction. Dotted staining represents the association of Drp1 with SENP2-S, but not SENP2 and SENP2-M in
C3H10T1/2 cells. (F) Double labeling with the proximity ligation assay and the DsRed2-Mito staining detects the mitochondrial interaction of Drp1
and SENP2S. (G) Double labeling of DsRed2-Mito and Drp1 reveals its accumulations to the mitochondria upon the knockdown of SENP2.
Enlargements of the insets are shown at right (E–G). (H) IB analysis shows effectiveness of the SENP2 knockdown by siRNA, and mitochondrial
stabilization and sumoylation of Drp1 caused by the SENP2 reduction. The levels of actin and Cox IV are analyzed as loading controls. (I) Graph
illustrates the statistical analysis of mitochondrial morphology (p,0.01, n = 3, mean 6 SEM). Scale bars, 20 mm (D); 50 mm (E, F); 20 mm (G).
doi:10.1371/journal.pgen.1004579.g004
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Figure 5. SENP2-dependent regulation of mitochondrial dynamics is mediated through modulation of Drp1. Mitochondrial
morphology examined by DsRed2-Mito labeling (A–H, A9–H9) reveals that overexpression of Drp1 induces mitochondrial fission in HCT116 (A–B, A9–
B9) and HCT116-SENP2S (E–F, E9–F9). SUMO1 mediated mitochondrial fragmentation in HCT116 cells (A, A9, C, C9) is prohibited in HCT116-SENP2S (E,
E9, G, G9) cells. High levels of Drp1 are capable of reversing the protected effect of SENP2 on mitochondrial fission (D, D9, H, H9). Enlargement of the
insets (A–H) are shown in A9–H9. (I) Graphs show the statistical analysis of mitochondrial morphology affected by Drp1 and SENP2 (p,0.01, n = 3,
mean 6 SEM). Scale bars, 20 mm (A–H).
doi:10.1371/journal.pgen.1004579.g005
SENP2 in Neurodegenerative Diseases
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in neural development and disease. Furthermore, Drp1 regula-
tion by the SUMO pathway is causally linked to neural
degeneration.
The SENP2 deficiency causes cell survival issues through
increases in mitochondrial fission, leading to the development of
neurodegeneration. As Drp1 appears to be a direct substrate of
SENP2, dysregulation of mitochondrial dynamics is likely the
primary cause of defects induced by the SENP2 disruption.
Further study of mice with aberrant expression of Drp1 in the
neural cells promises new insight into this regulatory mechanism.
It remains possible that the aberrant mitochondrial phenotype is
one of the main causes, which acts parallel with another cellular
abnormality or is a consequence of other cellular abnormalities,
e.g. failure of neural connection. Therefore, it is interesting to test
if prevention of mitochondrial apoptosis can alleviate the defects
caused by SENP2 deficiency. Further examination on the role of
mitochondria dynamics promises new insight into the SENP2-
mediated neuronal cell death.
The involvement of SENP2 in neural development and
degeneration opens new opportunities to develop therapeutic
targets in the SUMO pathway. As sumoylation has been shown to
counter against ubiquitination, manipulation of the SUMO
pathway may also alter the ubiquitination-mediated degradation
for the prevention and treatment of neurological disorders.
Although SENP2 may have a general effect on the neurons, it
remains possible that a specific subtype is more sensitive to the loss
of SENP2. In the SENP2 mutants, we identify different degrees of
neurodegeneration in the cerebral cortex, hippocampus, cerebel-
lum and spinal cord with the cerebral cortex being most severely
affected. A disruption of SENP2 in a specific neuronal subtype
may further divulge its role in neurodegenerative diseases. Testing
the protective role of SENP2 in neural cell survival in disease
conditions is also likely to gain a knowledge base of neurodegen-
erative diseases, leading to new therapeutic strategies.
Materials and Methods
DNA and cell
The pCS2-SENP2, pHASUMO1, pGEX-4T-SAE1/2, pGEX-
2T-Ubc9, pCS2-SENP2, pCS2-SENP2M and pCS2-SENP2S
DNA plasmids were described previously [16]. The pGEX-2T-
Drp1 clone was generated by inserting a DNA fragment encoding
Drp1 into the pGEX-2T vector (GE HealthCare). The SRa-HA-
SUMO2, pcDNA3-HA-SUMO3 and pDsRed2-Mito clones were
from Addgene or Clontech Laboratories. C3H10T1/2 and
HCT116 cells and their derivatives were cultured in DMEM
media with 10% fetal bovine serum and antibiotics [16,38].
Isolation, culture and differentiation of primary neural progenitor
cells were performed as described [38,39].
Mouse strains
The SENP2DSUMOFx ES cell lines were generated by electro-
poration of a targeting vector, containing the insertion of an
orphan loxP site in intron 15 and another loxP site and a pgk-neo
cassette flanked by two FRT sites in intron 16, into CSL3 ES cells
[17,40,41]. Twenty mouse ES cell clones heterozygous for the
targeted allele were obtained by homologous recombination
(targeting efficiency: 23/112). Two independent clones were
injected into blastocysts to generate chimeras which were bred
to obtain mice carrying the targeted allele. These mice were then
crossed with the R26Flp mice to remove the pgk-neo cassette to
obtain the SENP2DSUMOFx mouse strain. Mice were genotyped
by PCR analysis using primers (59-TCTCACTTGAAACCG-
TAGGGACC-39 and 59-GAAGGAAGGACTGGAGGAGAGA-
AG-39) to identify the 59 loxP locus, primers (59-TTGTCA-
GAAGCAGTGTCCTGCG-39 and 59-GACTGGGAAGATAT-
GAACTCGGC-39) to identify the 39 loxP locus. The deleted allele
was identified using primers (59-TCTCACTTGAAACCGTAGG-
GACC-39 and 59-GACTGGGAAGATATGAACTCGGC-39).
The PCR was performed by denaturation at 95uC for 5 min
and 35 cycles of amplification (95uC for 30 s, 67uC for 30 s, and
72uC for 60 s), followed by a 7-min extention at 72uC. The
SENP2lacZ and Nestin-Cre mouse strains and genotyping methods
were reported previously [17,40]. To generate the SENP2DSUMO
mouse strain expressing a deficient protein, mice carrying the
SENP2DSUMOFx allele were crossed with EIIa-Cre transgenic
mice to delete the protease core domain in the germ cells [41]. To
examine the production of SENP2 transcript, the reverse
transcription products were subject to PCR amplifications using
primers 59-CAGTCTCTACAATGCTGCC-39 and 59-CTGTC-
ACTCTGATCTTTGG-39 (exons 3–5), primers 59-GTGAGCT-
CATGAGTTCTGG-39 and 59-GTCGCTCCAATAACTTT-
CG-39 (exons 5–7), primers 59-GGAGGAGCAGAATCATGG-
39 and 59-CTCAAAATCTCATCTGGTGG-39(exons 8–11) and
primers 59-AGGTACATTGGAGCCTGGTG-39 and 59-AG-
CAACTGCTGGTGAAGGAT-39 (exons 13–17). The PCR
reaction was performed by denaturation at 94uC for 5 min and
30 cycles of amplification (94uC for 30 s, 53uC for 30 s, and 72uC
for 45 s), followed by a 7-min extension at 72uC. Care and use of
experimental animals described in this work were approved by and
comply with guidelines and policies of the University of
Committee on Animal Resources at the University of Rochester.
Histology, in situ hybridization and TUNEL analysis
Samples were fixed, paraffin embedded, sectioned and stained
with hematoxylin/eosin for histological evaluation [17,42]. The in
situ hybridization was performed as described [17,38,43,44]. In
brief, sections were incubated with the digoxygenin labeled RNA
probes generated by in vitro transcription [17,43], followed by
recognition with an alkaline phosphatase conjugated anti-digox-
ygenin antibody and visualization with BM-purple [38,44].
TUNEL staining was performed with ApopTag (Millipore) as
described [45,46]. For electron microscopy, mice were fixed by
perfusion with fixative (2% paraformaldehyde, 2.5% Glutaralde-
hyde, 0.1M sodium cacodylate, 6.8% sucrose). The dissected
tissues were then fixed with 1% osmium tetroxide, embedded in
EPON/Araldite resin and cut in seventy nm sections, followed by
staining with aqueous uranyl acetate and lead citrate and
examined using Hitachi 7650 transmission electron microscope.
Proximity ligation assay, immunostaining, immunoblot
and immunoprecipitation
Proximity ligation assay (PLA) was performed using Duolink In
Situ reagents (Duolink Bioscience). Briefly, cells were fixed and
incubated with rabbit anti-Drp1 and mouse anti-myc tag antibod-
ies. Two oligonucleotide-labeled anti-rabbit and anti-mouse PLA
probes, which bind to each other when they are in close proximity,
were then used to generate fluorescent signals. Immunostaining of
cells [47] and tissue sections [48–50] were performed by incubation
with primary antibodies, followed by detection with fluorescence-
conjugated or horseradish peroxidase-conjugated secondary anti-
bodies. Images were taken using Zeiss Axio Observer microscope
equipped with deconvolution analysis. To determine the mitochon-
drial morphology, cells were either stained by MitoTracker or
transient expression of DsRed2-Mito. For statistical analysis, cells
containing MitoTracker or DsRed2-Mito positive mitochondria
were counted and scored for tubular/rod-like or fragmented
mitochondria. Immunoblot was performed by isolation of protein
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extracts from mitochondria, cells or tissues using M-PER (Pierce) in
the presence of protease inhibitor cocktail, followed by electropho-
resis as described [16,17,38,48]. Isolation of mitochondria was
performed using a Mitochondria Isolation Kit (Thermo Fisher)
according to the manufacture’s description. Immunoprecipitation
was performed using Pierce Classic IP Kit. Briefly, cells were lysed
in buffer containing 0.025M Tris, 0.15M NaCl, 0.001M EDTA,
1% NP-40, 5% glycerol. Approximately 500 mg of protein lysates
were mixed with 2 mg of antibodies overnight, followed by
incubation with Protein A/G agarose for 1 hour at 4uC. The
antibody-bound complex was then incubated with elution buffer for
5 min at 100uC, and collected by centrifugation for SDS-PAGE
analysis. Mouse monoclonal antibodies, Actin (Thermo Fisher), HA
(Cell Signaling), and myc tag (Santa Cruz); rabbit polyclonal
antibodies Bak (Novus Biologicals), caspase-3 (BD Biosciences), Cox
IV (Cell Signaling), Drp1 (Novus Biologicals), and SUMO1 (Cell
Signaling), were used in these analyses.
Sumoylation and desumoylation
Recombinant GST-SAE1/SAE2, GST-Ubc9, GST-Drp1, HA-
SUMO1 and myc tagged (MT)-SENP2 proteins expressed in
Escherichia coli were affinity purified. The 20-ml reaction buffer
containing 50 mM Tris-HCl (pH 7.6), 5 mM magnesium chlo-
ride, 10 mM ATP, 1 mg of GST-ASE1/2, 2 mg of GST-Ubc9,
10 mg of GST-HA-SUMO1 and 200 ng of GST-Drp1 with the
presence of protease inhibitor cocktail was incubated for 3 h at
37uC. The desumoylation reaction was then carried out in 10 ml of
the above sumoylation mixture with the addition of purified MT-
SENP2 for overnight at 37uC. The samples were then analyzed by
SDS-PAGE and immunoblot analysis of Drp1 and SUMO1.
Supporting Information
Figure S1 Whole mount (A, B) and histological (C, D) analyses
of the E10.5 SENP2+/+ (A, C) and SENP22/2 (B, D) embryos
reveal brain abnormalities (arrows) caused by total knockout
(embryonic and extra-embryonic ablation) of SENP2. TUNEL
staining in whole mounts (E, F) and sections (G, H) identifies an
increase in apoptotic cells associated with the SENP2 deletion.
The images shown are representatives of more than three
independent experiments. Scale bars, 1 mm (A–F); 100 mm (G,
H).
(TIF)
Figure S2 Diagram illustrates the creation of mice carrying
SENP2DSUMOFx allele. (A) Exon 16 (Ex16), containing the
protease core domain, is flanked by two loxP sites. Removal of
exon 16 causes an in-frame deletion, resulting in production of an
internally truncated SENP2 protein. (B) Southern blot analysis
with 39 and 59 external probes identifies ES cell clones carrying the
targeted allele. (C) PCR analysis detects the presence of 59 (P1–P2)
and 39 (P3–P4) loxP sites for genotyping the wild-type (+/+) and
heterozygous (Fx/+) SENP2DSUMOFx mice, and examines the
deletion of exon 16 in the SENP2DSUMOD/+ mice (P1–P4). (D)
RT-PCR analyzes the SENP2 RNA transcribed in the wild type
(+/+), heterozygous (+/2) and homozygous (2/2) embryos. No
difference in exon 3–5, exon 5–7 and exon 8–11 is found. A
smaller RT-PCR product for exon 13–17 is detected in the mutant
due to Cre-mediated in-frame deletion of exon 16.
(TIF)
Figure S3 The SENP2DSUMO homozygous mutants exhibit
embryonic and extraembryonic abnormalities. Whole mount (A–
B) and histological (C–J) evaluations of the E10.5 wild type (A, C,
E, G, I) and mutant (B, D, F, H, J) embryos (A–B) and placentas
(C–J) reveal that deletion of the SUMO protease core domain
results in embryonic and extraembryonic defects highly reminis-
cent to the SENP2 nulls. Labyrinth (L), spongiotrophoblast (S),
trophoblast giant cell (G) layers are defined by blue, red and green
broken lines, respectively. Arrow and arrowheads indicate
maternal and fetal blood spaces, respectively. The images shown
are representatives of three independent experiments. Scale bars,
1 mm (A–B), 500 mm (C–D), 50 mm (E–J).
(TIF)
Figure S4 Nestin-Cre transgene induces site-specific recombi-
nation in neural development. The efficacy of DNA recombina-
tion medicated by Nestin-Cre is examined by an R26RlacZ
reporter allele. Examination of embryos carrying Nestin-Cre and
R26RlacZ by b-gal staining in whole mount (A–B, C–D) and
section (a–d) demonstrates the efficacy of Cre-mediated recombi-
nation in neural progenitor cells at E10.5 (A–B, a–c) and E12.5
(C–D, d). The approximate positions of a–d are shown by the
broken line in B and D. fb, forebrain; hb, hindbrain; mb,
midbrain; nt, neural tube. Scale bars, 1 mm (A–D, d); 100 mm (a–
c).
(TIF)
Figure S5 The loss of SENP2 affects CNS development.
Hematoxylin and eosin staining analyzes development of the
control (genotype: Nestin-Cre; SENP2SUMOFx/+ and SENP2SU-
MOFx/Fx) and SENP2DSUMO-Nes midbrains, cerebella, hippocam-
pi and spinal cords at P14. The mutation causes size reduction in
these areas. Compared to the control, mutant neural cells are
loosely distributed (arrows), presenting evidence for neurodegen-
eration. Enlargements of the insets (A–H) are shown in A9–H9.
Scale bars, 500 mm (A–H); 50 mm (A9–H9).
(TIF)
Figure S6 Abnormal apoptosis is detected in the SENP2
mutants during CNS development. TUNEL staining examines
apoptotic cells in the control (genotype: Nestin-Cre; SENP2SU-
MOFx/+ and SENP2SUMOFx/Fx) and SENP2DSUMO-Nes mid-
brains, cerebella, hippocampi and spinal cords at P7. The
mutation enhances apoptosis in these areas. Enlargements of the
insets (A–H) are shown in A9–H9. The images shown are
representatives of three independent experiments. Scale bars,
500 mm (A–H); 50 mm (A9–H9).
(TIF)
Figure S7 The deletion of SENP2 affects Drp1 association with
the mitochondria. Co-labeling of mitochondria by MitoTracker
(red), endogenous Drp1 by immunostaining (green), and nuclei
(blue), shows differential association of Drp1 with the mitochon-
dria in control and mutant. Enlargements of the inset are shown in
the bottom panel. Arrows, arrowheads and asterisk indicate
tubular/rod-like mitochondria, fragmented mitochondria and
Drp1 association with the mitochondria, respectively. The images
are representatives of three independent experiments. Scale bars,
20 mm.
(TIF)
Figure S8 SUMO2 and SUMO3 are not involved in the
SENP2-mediated modification of Drp1. (A) Immunoblot (IB)
analysis examines the expression of HA-SUMO2, Drp1 and Actin
in HCT116 cells and in HCT116 stably transformed variants,
HCT116-SENP2, HCT116-SENP2M and HCT116-SENP2S. (B)
IB analysis examines the expression of HA-SUMO3, Drp1 and
Actin in HCT116 cells and in HCT116 stably transformed
variants, HCT116-SENP2, HCT116-SENP2M and HCT116-
SENP2S. Overexpression of HA-SUMO2 (A) or HA-SUMO3 (B)
induces sumoylation in HCT116 cells and in HCT116 stably
SENP2 in Neurodegenerative Diseases
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transformed variants, HCT116-SENP2, HCT116-SENP2M and
HCT116-SENP2S. No significant difference in Drp1 expression is
found in HCT116 cells and HCT116 variants. Actin level serves as
a protein loading control.
(TIF)
Video S1 A clip shows movement difficulties of the P10




We thank George A. Porter, Yisang Yoon and University of Rochester
Electron Microscope Research Core for reagents and assistance, and
Richard T. Libby and Robert Freeman for comments and suggestions.
Author Contributions
Conceived and designed the experiments: JF HMIY SYC EOM JGC WH.
Performed the experiments: JF HMIY SYC AJM EOM JGC WH.
Analyzed the data: JF HMIY SYC AJM EOM JGC WH. Wrote the paper:
JF AJM WH.
References
1. Martin S, Nishimune A, Mellor JR, Henley JM (2007) SUMOylation regulates
kainate-receptor-mediated synaptic transmission. Nature 447: 321–325.
2. Shalizi A, Gaudilliere B, Yuan Z, Stegmuller J, Shirogane T, et al. (2006) A
calcium-regulated MEF2 sumoylation switch controls postsynaptic differentia-
tion. Science 311: 1012–1017.
3. Flavell SW, Cowan CW, Kim TK, Greer PL, Lin Y, et al. (2006) Activity-
dependent regulation of MEF2 transcription factors suppresses excitatory
synapse number. Science 311: 1008–1012.
4. Krumova P, Weishaupt JH (2013) Sumoylation in neurodegenerative diseases.
Cell Mol Life Sci 70: 2123–2138.
5. Lieberman AP (2004) SUMO, a ubiquitin-like modifier implicated in
neurodegeneration. Exp Neurol 185: 204–207.
6. Martin S, Wilkinson KA, Nishimune A, Henley JM (2007) Emerging
extranuclear roles of protein SUMOylation in neuronal function and
dysfunction. Nat Rev Neurosci 8: 948–959.
7. Seeler JS, Dejean A (2003) Nuclear and unclear functions of SUMO. Nat Rev
Mol Cell Biol 4: 690–699.
8. Ouyang J, Valin A, Gill G (2009) Regulation of transcription factor activity by
SUMO modification. Methods Mol Biol 497: 141–152.
9. Geoffroy MC, Hay RT (2009) An additional role for SUMO in ubiquitin-
mediated proteolysis. Nat Rev Mol Cell Biol 10: 564–568.
10. Cubenas-Potts C, Matunis MJ (2013) SUMO: a multifaceted modifier of
chromatin structure and function. Dev Cell 24: 1–12.
11. Ulrich HD (2009) The SUMO system: an overview. Methods Mol Biol 497: 3–
16.
12. Melchior F (2000) SUMO–nonclassical ubiquitin. Annu Rev Cell Dev Biol 16:
591–626.
13. Gareau JR, Lima CD (2010) The SUMO pathway: emerging mechanisms that
shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 11: 861–
871.
14. Melchior F, Schergaut M, Pichler A (2003) SUMO: ligases, isopeptidases and
nuclear pores. Trends Biochem Sci 28: 612–618.
15. Hickey CM, Wilson NR, Hochstrasser M (2012) Function and regulation of
SUMO proteases. Nat Rev Mol Cell Biol 13: 755–766.
16. Jiang M, Chiu SY, Hsu W (2011) SUMO-specific protease 2 in Mdm2-mediated
regulation of p53. Cell Death Differ 18: 1005–1015.
17. Chiu SY, Asai N, Costantini F, Hsu W (2008) SUMO-Specific Protease 2 Is
Essential for Modulating p53-Mdm2 in Development of Trophoblast Stem Cell
Niches and Lineages. PLoS Biol 6: e310.
18. Kang X, Qi Y, Zuo Y, Wang Q, Zou Y, et al. (2010) SUMO-specific protease 2
is essential for suppression of polycomb group protein-mediated gene silencing
during embryonic development. Mol Cell 38: 191–201.
19. Shinbo Y, Niki T, Taira T, Ooe H, Takahashi-Niki K, et al. (2006) Proper
SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death
Differ 13: 96–108.
20. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, et al. (2004)
SUMO modification of Huntingtin and Huntington’s disease pathology. Science
304: 100–104.
21. Pountney DL, Huang Y, Burns RJ, Haan E, Thompson PD, et al. (2003)
SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear
inclusion disease. Exp Neurol 184: 436–446.
22. Riley BE, Zoghbi HY, Orr HT (2005) SUMOylation of the polyglutamine
repeat protein, ataxin-1, is dependent on a functional nuclear localization signal.
J Biol Chem 280: 21942–21948.
23. Hattori N, Mizuno Y (2004) Pathogenetic mechanisms of parkin in Parkinson’s
disease. Lancet 364: 722–724.
24. Ren D, Tu HC, Kim H, Wang GX, Bean GR, et al. (2010) BID, BIM, and
PUMA are essential for activation of the BAX- and BAK-dependent cell death
program. Science 330: 1390–1393.
25. Wasiak S, Zunino R, McBride HM (2007) Bax/Bak promote sumoylation of
DRP1 and its stable association with mitochondria during apoptotic cell death.
J Cell Biol 177: 439–450.
26. Cho DH, Nakamura T, Fang J, Cieplak P, Godzik A, et al. (2009) S-nitrosylation
of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal
injury. Science 324: 102–105.
27. Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, et al. (2010)
Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease.
Hum Mol Genet 19: 3919–3935.
28. Pitts KR, Yoon Y, Krueger EW, McNiven MA (1999) The dynamin-like protein
DLP1 is essential for normal distribution and morphology of the endoplasmic
reticulum and mitochondria in mammalian cells. Mol Biol Cell 10: 4403–4417.
29. Krumova P, Meulmeester E, Garrido M, Tirard M, Hsiao HH, et al. (2011)
Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol 194:
49–60.
30. Li Y, Wang H, Wang S, Quon D, Liu YW, et al. (2003) Positive and negative
regulation of APP amyloidogenesis by sumoylation. Proc Natl Acad Sci U S A
100: 259–264.
31. Bender T, Martinou JC (2013) Where killers meet–permeabilization of the outer
mitochondrial membrane during apoptosis. Cold Spring Harb Perspect Biol 5:
a011106.
32. Mali P, Esvelt KM, Church GM (2013) Cas9 as a versatile tool for engineering
biology. Nat Methods 10: 957–963.
33. Reddy PH, Reddy TP, Manczak M, Calkins MJ, Shirendeb U, et al. (2011)
Dynamin-related protein 1 and mitochondrial fragmentation in neurodegener-
ative diseases. Brain Res Rev 67: 103–118.
34. Chan DC (2012) Fusion and fission: interlinked processes critical for
mitochondrial health. Annu Rev Genet 46: 265–287.
35. Harder Z, Zunino R, McBride H (2004) Sumo1 conjugates mitochondrial
substrates and participates in mitochondrial fission. Curr Biol 14: 340–345.
36. Zunino R, Schauss A, Rippstein P, Andrade-Navarro M, McBride HM (2007)
The SUMO protease SENP5 is required to maintain mitochondrial morphology
and function. J Cell Sci 120: 1178–1188.
37. Zunino R, Braschi E, Xu L, McBride HM (2009) Translocation of SenP5 from
the nucleoli to the mitochondria modulates DRP1-dependent fission during
mitosis. J Biol Chem 284: 17783–17795.
38. Fu J, Jiang M, Mirando AJ, Yu HM, Hsu W (2009) Reciprocal regulation of
Wnt and Gpr177/mouse Wntless is required for embryonic axis formation. Proc
Natl Acad Sci U S A 106: 18598–18603.
39. Yu HM, Jin Y, Fu J, Hsu W (2010) Expression of Gpr177, a Wnt trafficking
regulator, in mouse embryogenesis. Dev Dyn 239: 2102–2109.
40. Yu HM, Liu B, Chiu SY, Costantini F, Hsu W (2005) Development of a unique
system for spatiotemporal and lineage-specific gene expression in mice. Proc
Natl Acad Sci U S A 102: 8615–8620.
41. Fu J, Ivy Yu HM, Maruyama T, Mirando AJ, Hsu W (2011) Gpr177/mouse
Wntless is essential for Wnt-mediated craniofacial and brain development. Dev
Dyn 240: 365–371.
42. Yu HM, Jerchow B, Sheu TJ, Liu B, Costantini F, et al. (2005) The role of Axin2
in calvarial morphogenesis and craniosynostosis. Development 132: 1995–2005.
43. Fu J, Hsu W (2013) Epidermal Wnt controls hair follicle induction by
orchestrating dynamic signaling crosstalk between the epidermis and dermis.
J Invest Dermatol 133: 890–898.
44. Maruyama T, Jiang M, Hsu W (2013) Gpr177, a novel locus for bone mineral
density and osteoporosis, regulates osteogenesis and chondrogenesis in skeletal
development. J Bone Miner Res 28: 1150–1159.
45. Maruyama T, Mirando AJ, Deng CX, Hsu W (2010) The balance of WNT and
FGF signaling influences mesenchymal stem cell fate during skeletal develop-
ment. Sci Signal 3: ra40.
46. Yu HM, Liu B, Costantini F, Hsu W (2007) Impaired neural development
caused by inducible expression of Axin in transgenic mice. Mech Dev 124: 146–
156.
47. Liu B, Yu HM, Hsu W (2007) Craniosynostosis caused by Axin2 deficiency is
mediated through distinct functions of beta-catenin in proliferation and
differentiation. Dev Biol 301: 298–308.
48. Liu B, Yu HM, Huang J, Hsu W (2008) Co-opted JNK/SAPK signaling in
Wnt/beta-catenin-induced tumorigenesis. Neoplasia 10: 1004–1013.
49. Mirando AJ, Maruyama T, Fu J, Yu HM, Hsu W (2010) Beta-catenin/cyclin D1
mediated development of suture mesenchyme in calvarial morphogenesis. BMC
Dev Biol 10: 116.
50. Maruyama EO, Yu HM, Jiang M, Fu J, Hsu W (2013) Gpr177 deficiency
impairs mammary development and prohibits Wnt-induced tumorigenesis.
PLoS One 8: e56644.
SENP2 in Neurodegenerative Diseases
PLOS Genetics | www.plosgenetics.org 11 October 2014 | Volume 10 | Issue 10 | e1004579
